154 related articles for article (PubMed ID: 7698151)
41. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
42. Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer.
Kalofonos HP; Sackier JM; Hatzistylianou M; Pervez S; Taylor-Papadimitriou J; Waxman JH; Lavender JP; Wood C; Epenetos AA
Br J Cancer; 1989 Jun; 59(6):939-42. PubMed ID: 2736231
[TBL] [Abstract][Full Text] [Related]
43. [Labeling of antihuman bladder carcinoma monoclonal antibody with a technetium-99m and radioimmunoimaging of human bladder carcinoma xenograft in nude mice].
Samten B; Yu L; Zhang C
Zhonghua Wai Ke Za Zhi; 1996 Jan; 34(1):10-2. PubMed ID: 9275678
[TBL] [Abstract][Full Text] [Related]
44. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin.
Paganelli G; Belloni C; Magnani P; Zito F; Pasini A; Sassi I; Meroni M; Mariani M; Vignali M; Siccardi AG
Eur J Nucl Med; 1992; 19(5):322-9. PubMed ID: 1612093
[TBL] [Abstract][Full Text] [Related]
45. Effect of interleukin-2 on the biodistribution of technetium-99m-labelled anti-CEA monoclonal antibody in mice bearing human tumour xenografts.
Nakamura K; Kubo A
Eur J Nucl Med; 1994 Sep; 21(9):924-9. PubMed ID: 7995285
[TBL] [Abstract][Full Text] [Related]
46. Clinical application of radioimmunoimaging with 99mTc-BDI-1 in the diagnosis of bladder cancer.
Wang R; Zhang C; Yu L; Guo Y
Chin Med J (Engl); 2000 May; 113(5):396-9. PubMed ID: 11776091
[TBL] [Abstract][Full Text] [Related]
47. Tc-99m MDP uptake in a calcified bladder tumor.
Rohren EM
Clin Nucl Med; 2001 Jan; 26(1):58-9. PubMed ID: 11139057
[TBL] [Abstract][Full Text] [Related]
48. Targeting of tumours with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: immunolocalisation, pharmacokinetics and immune response.
Kalofonos HP; Kosmas C; Hird V; Snook DE; Epenetos AA
Eur J Cancer; 1994; 30A(12):1842-50. PubMed ID: 7880616
[TBL] [Abstract][Full Text] [Related]
49. Incrustation and uptake of skeletal imaging agent in transitional cell carcinoma.
Taniguchi M; Tatsuta N; Yokota H; Ouguchi M; Higashi K; Okimura T; Yamamoto I
J Nucl Med; 1997 Aug; 38(8):1206-7. PubMed ID: 9255150
[TBL] [Abstract][Full Text] [Related]
50. Transurethral Resection of the Bladder Tumour as a Treatment Method in Children with Transitional Cell Carcinoma of the Bladder--Analysis of Our Material and Literature Review.
Apoznański W; Rysiakiewicz J; Polok M; Rysiakiewicz K; Siekanowicz P; Hilger T; Zagierski J; Hilger M; Nowak I; Kolęda P; Szydełko T
Adv Clin Exp Med; 2015; 24(3):505-9. PubMed ID: 26467141
[TBL] [Abstract][Full Text] [Related]
51. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin.
Paganelli G; Magnani P; Zito F; Lucignani G; Sudati F; Truci G; Motti E; Terreni M; Pollo B; Giovanelli M
Eur J Nucl Med; 1994 Apr; 21(4):314-21. PubMed ID: 8005155
[TBL] [Abstract][Full Text] [Related]
52. Semiquantitative SPECT tumor uptake of technetium-99m-labeled anti-CEA monoclonal antibody in colorectal tumor.
Oriuchi N; Endo K; Watanabe N; Sugiyama S; Asao T; Takenoshita S; Nagamachi Y; Baum RP
J Nucl Med; 1995 Apr; 36(4):679-83. PubMed ID: 7699464
[TBL] [Abstract][Full Text] [Related]
53. Bromodeoxyuridine labelling of transitional cell carcinoma of the bladder--an index of recurrence?
Popert RJ; Joyce AD; Thomas DJ; Walmsley BH; Coptcoat MJ
Br J Urol; 1993 Mar; 71(3):279-83. PubMed ID: 8477314
[TBL] [Abstract][Full Text] [Related]
54. Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer.
Bue P; Holmberg AR; Márquez M; Westlin JE; Nilsson S; Malmström PU
Eur Urol; 2000 Nov; 38(5):584-9. PubMed ID: 11096240
[TBL] [Abstract][Full Text] [Related]
55. [The clinical relevance of anti-CEA immunoscintigraphy with the 99mTc-labelled monoclonal antibody BW 431/26. A critical assessment after 119 studies].
Hach A; Wittig B; Piepenburg R; Steinert H; Lahmann C; Dippold W; Hahn K
Rofo; 1992 Jul; 157(1):3-10. PubMed ID: 1638001
[TBL] [Abstract][Full Text] [Related]
56. The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody.
Davidson BR; Babich J; Young H; Waddington W; Clarke G; Short M; Boulos P; Styles J; Dean C
Br J Cancer; 1991 Nov; 64(5):850-6. PubMed ID: 1931605
[TBL] [Abstract][Full Text] [Related]
57. Immunoscintigraphic localization of renal tumours in an extracorporeal perfusion model with a monoclonal antibody against gamma-glutamyltransferase.
Fischer P; Baum RP; Tauber M; Boeckmann W; Weier S; Scherberich JE
Cancer Immunol Immunother; 1992; 35(4):283-8. PubMed ID: 1355011
[TBL] [Abstract][Full Text] [Related]
58. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
[TBL] [Abstract][Full Text] [Related]
59. Intravenous urography in patients with transitional cell carcinoma of the bladder. The incidence and implications of ureteral obstruction.
Allen FJ; Steenkamp JW
S Afr J Surg; 1992 Mar; 30(1):28-32. PubMed ID: 1566202
[TBL] [Abstract][Full Text] [Related]
60. Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21.
Hoebers FJ; Janssen HL; Olmos AV; Sprong D; Nunn AD; Balm AJ; Hoefnagel CA; Begg AC; Haustermans KM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1206-11. PubMed ID: 12192567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
